Janus Henderson Group PLC Raises Stock Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL)

Janus Henderson Group PLC increased its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned approximately 9.15% of Precision BioSciences worth $6,322,000 as of its most recent filing with the Securities and Exchange Commission.

Precision BioSciences Trading Up 1.5 %

NASDAQ DTIL opened at $5.95 on Tuesday. The company has a 50-day moving average of $8.05 and a 200-day moving average of $9.40. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. Precision BioSciences, Inc. has a 12 month low of $5.78 and a 12 month high of $19.43. The company has a market cap of $45.64 million, a P/E ratio of 99.17 and a beta of 1.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research note on Thursday, August 22nd.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.